Safety, healing, and efficacy of vascular prostheses coated with hydroxypropyl-β-cyclodextrin polymer: Experimental in vitro and animal studies

European Journal of Vascular and Endovascular Surgery

Volumn 43, Issue 2, 2012, Pages 188-197

  Jean Baptiste, E ^a,b,c,d   Blanchemain, N ^a,b   Martel, B ^a,e   Neut, C ^a,f   Hildebrand, H F ^a,b   Haulon, S ^a,b,c  

^a UNIV LILLE   (France)

^b France   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d University Hospital of Nice University of Nice Sophia Antipolis   (France)

^e UNIVERSITÉ LILLE 1   (France)

^f UNIVERSITÉ DE LILLE   (France)

Author keywords

Blood vessel prosthesis; Cyclodextrins; Drug delivery systems; Prosthesis related infections

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ANTIBIOTIC AGENT;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BIOCOMPATIBILITY; BIODEGRADATION; BLOOD; BLOOD ANALYSIS; BLOOD VESSEL PROSTHESIS; CONTROLLED STUDY; FEMALE; HEALING; HEMOLYSIS; HISTOLOGY; HUMAN; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-CYCLODEXTRINS; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CIPROFLOXACIN; COATED MATERIALS, BIOCOMPATIBLE; DOGS; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HEMOLYSIS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; PLATELET AGGREGATION; PROSTHESIS-RELATED INFECTIONS; RIFAMPIN; TOXICITY TESTS; TREATMENT OUTCOME; VANCOMYCIN; WOUND HEALING;

EID: 84855537812     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2011.10.017     Document Type: Article

References (29)

1. Marois Y, Chakfe N, Deng X, Marois M, How T, King MW, et al. Carbodiimide cross-linked gelatin: a new coating for porous polyester arterial prostheses. Biomaterials 1995;16:1131-9.
2. Quinones-Baldrich WJ, Moore WS, Ziomek S, Chvapil M. Development of a "leak-proof," knitted Dacron vascular prosthesis. J Vasc Surg 1986;3:895-903. (Pubitemid 16036211)
3. Tolan M, Wells F, Kendall S, Large S,Wallwork J. Clinical experience with a collagen impregnated woven Dacron graft. J Cardiovasc Surg (Torino) 1995;36:323-7.
4. O'Brien T, Collin J. Prosthetic vascular graft infection. Br J Surg 1992;79:1262-7. (Pubitemid 23008375)
5. Blanchemain N, Laurent T, Chai F, Neut C, Haulon S, Krump-konvalinkova V, et al. Polyester vascular prostheses coated with a cyclodextrin polymer and activated with antibiotics: cytotoxicity and microbiological evaluation. Acta Biomater 2008;4:1725-33.
6. Jean-Baptiste E, Batt M, Brizzy S,Mousnier A, DeclemyS, Hassen-Khodja R. Dealing with vascular graft infection, including aortic enteric fistulas. In: Jacobs M, editor. Prevention and management of vascular complications 2011. p. 81-96. Milan.
7. Martel B, Morcellet M, Ruffin D, Ducoroy L, Weltrowski M. Finishing of polyester fabrics by cyclodextrins by using polycarboxylic acids as crosslinking agents. J Incl Phen Macr Chem 2002;44:443-6. (Pubitemid 38075741)
8. Blanchemain N, Haulon S, Boschin F, Marcon-Bachari E, Traisnel M, Morcellet M, et al. Vascular prostheses with controlled release of antibiotics Part 1: surface modification with cyclodextrins of PET prostheses. Biomol Eng 2007;24:149-53. (Pubitemid 46223547)
9. Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci 1996;85:1142-69. (Pubitemid 26372882)
10. Loftsson T, Jarho P, Masson M, Jarvinen T. Cyclodextrins in drug delivery. Expert Opin Drug Deliv 2005;2:335-51. (Pubitemid 41130887)
11. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 1996;85:1017-25. (Pubitemid 26338912)
12. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci 1997;86:147-62. (Pubitemid 27078377)
13. Shimpi S, Chauhan B, Shimpi P. Cyclodextrins: application in different routes of drug administration. Acta Pharm 2005;55:139-56. (Pubitemid 40992426)
14. Gould S, Scott RC. 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. Food Chem Toxicol 2005;43:1451-9.
15. Martel B, Ruffin D, Morcellet M, Weltrowski M, Lekchiri Y. Water soluble polymers and gels from polycondensation between cyclodextrins and polycarboxylic acids: study of the preparation parameters. J Appl Polym Sci 2005;97:433-42. (Pubitemid 40860169)
16. ISO10993-4. Biological evaluation of medical devices-Part 4: selection of tests for interactions with blood. Geneva, Switzerland: International Organization for Standardization; 2002.
17. Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 1966;45:493-6.
18. Neut D, Dijkstra RJ, Thompson JI, van der Mei HC, Busscher HJ. Antibacterial efficacy of a new gentamicin-coating for cementless prostheses compared to gentamicin-loaded bone cement. J Orthop Res 2011;29:1654-61.
19. USP28. National Formulatory 23, Biological Reactivity Test, In Vivo 2005.
20. Schuh JC. Medical device regulations and testing for toxicologic pathologists. Toxicol Pathol 2008;36:63-9.
21. Gupta B, Plummer C, Bisson I, Frey P, Hilborn J. Plasma-induced graft polymerization of acrylic acid onto poly(ethylene terephthalate) films: characterization and human smooth muscle cell growth on grafted films. Biomaterials 2002;23:863-71. (Pubitemid 33108961)
22. Jordan SW, Chaikof EL. Novel thromboresistant materials. J Vasc Surg 2007;45(Suppl. A):A104-15.
23. Murphy JG, Schwartz RS, Edwards WD, Camrud AR, Vlietstra RE, Holmes Jr DR. Percutaneous polymeric stents in porcine coronary arteries. Initial experience with polyethylene terephthalate stents. Circulation 1992;86:1596-604.
24. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med 2006;354:483-95. (Pubitemid 43200299)
25. Carrier RL, Miller LA, Ahmed I. The utility of cyclodextrins for enhancing oral bioavailability. J Control Release 2007;123:78-99. (Pubitemid 47566400)
26. Arima H, Hirayama F, Okamoto C, Uekama K. Recent aspects of cyclodextrin-based pharmaceutical formulations. Recent Res Dev Chem Pharm Sci 2002;2:155-93.
27. Irie T, Otagiri M, Sunada M, Uekama K, Ohtani Y, Yamada Y, et al. Cyclodextrin-induced hemolysis and shape changes of human erythrocytes in vitro. J Pharmacobio-Dyn 1982;5:741-4. (Pubitemid 13219471)
28. Stewart A, Eyers PS, Earnshaw JJ. Prevention of infection in arterial reconstruction. Cochrane Database Syst Rev 2006;3:CD003073.
29. Otto M. Staphylococcus epidermidis-the 'accidental' pathogen. Nat Rev Microbiol 2009;7:555-67.